Veracyte Ownership
| VCYT Stock | USD 42.89 0.05 0.12% |
Shares in Circulation | First Issued 2012-09-30 | Previous Quarter 77.2 M | Current Value 78.5 M | Avarage Shares Outstanding 44 M | Quarterly Volatility 21.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Veracyte |
Veracyte Stock Ownership Analysis
About 99.0% of the company outstanding shares are owned by institutional investors. The book value of Veracyte was at this time reported as 15.18. The company recorded a loss per share of 0.13. Veracyte had not issued any dividends in recent years. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis Prosigna Breast Cancer Assay for breast cancer diagnosis Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis and Immunoscore Colon Cancer test for colon cancer diagnosis. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Veracyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 761 people. For more information please call Bonnie Anderson at 650 243 6300 or visit https://www.veracyte.com.Besides selling stocks to institutional investors, Veracyte also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Veracyte's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Veracyte's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Veracyte Quarterly Liabilities And Stockholders Equity |
|
Veracyte Insider Trades History
Less than 1% of Veracyte are currently held by insiders. Unlike Veracyte's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Veracyte's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Veracyte's insider trades
Veracyte Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Veracyte is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Veracyte backward and forwards among themselves. Veracyte's institutional investor refers to the entity that pools money to purchase Veracyte's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.8 M | Bank Of America Corp | 2024-06-30 | 1.8 M | Gw&k Investment Management, Llc | 2024-09-30 | 1.4 M | Bamco Inc | 2024-09-30 | 1.1 M | Goldman Sachs Group Inc | 2024-06-30 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 950.8 K | Northern Trust Corp | 2024-09-30 | 948.4 K | Fisher Asset Management, Llc | 2024-09-30 | 877.8 K | William Blair Investment Management, Llc | 2024-09-30 | 811.8 K | Blackrock Inc | 2024-06-30 | 7.8 M | Vanguard Group Inc | 2024-09-30 | 7.7 M |
Veracyte Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Veracyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Veracyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Veracyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Veracyte Outstanding Bonds
Veracyte issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Veracyte uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Veracyte bonds can be classified according to their maturity, which is the date when Veracyte has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Veracyte Corporate Filings
F4 | 21st of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.